ArticlePakistan journal of medical sciences2025
Clinical efficacy and safety of transarterial chemoembolization combined with targeted therapy and PD1 inhibitors in patients with advanced liver cancer.
Article in Pakistan journal of medical sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Review Article: Biomarkers in Liver Transplantation for Hepatocellular Carcinoma: Towards Precision Medicine.Alimentary pharmacology & therapeutics · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To investigate the clinical efficacy and safety of transarterial chemoembolization(TACE) combined with targeted therapy and PD1 inhibitors in patients with advanced liver cancer. Methods: This was a retrospective study. A total of 120 patients with advanced primary liver cancer admitted to Affiliated Hospital of Hebei University were randomly divided into two groups, with 60 patients in each group from May 2020 to May 2023. Patients in the control group received conventional TACE, and those in the experimental group received 200 mg camrelizumab once every 21 days and oral lenvatinib mesylate capsules once daily in addition to TACE. Compared the clinical efficacy, levels of tumor markers, T lymphocyte subsets, and adverse drug reactions after treatment and the improvement of quality of life(QOL) before and after treatment between the two groups of patients. Results: The overall response rate(ORR) was 80% in the experimental group and 62% in the control group, and the difference was statistically significant(p=0.03); the incidence of adverse reactions was 28% in the experimental group and 25% in the control group, with no significant difference between the two groups(p=0.68); the improvement rate of QOL score was significantly increased(p=0.03) and the deterioration rate was significantly decreased(p=0.01) in the experimental group compared with those in the control group, respectively. Conclusion: TACE combined with targeted therapy and PD1 inhibitors is significantly effective to improve the cellular immune function with no significant increase in the incidence of adverse reactions, making it an effective and safe treatment option for patients with liver cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.